Regulatory

India moves to tighten drug supply chain rules, targets storage and distribution lapses

  • By IPP Bureau | November 22, 2026
India has proposed tighter regulations governing the storage, handling and distribution of pharmaceutical products, seeking to ensure that medicines retain their quality, safety and efficacy until they reach patients.
 
The Union Ministry of Health and Family Welfare has proposed incorporating Good Storage and Distribution Practices (GSDP) guidelines into the Drugs Rules, 1945, in a move aimed at strengthening oversight of India's pharmaceutical supply chain.
 
The proposed framework seeks to plug potential gaps in the handling and movement of medicines beyond the manufacturing stage, addressing risks such as deterioration, contamination, product mix-ups, falsification, diversion and unauthorised distribution.
 
Under the proposed guidelines, pharmaceutical products will have to maintain prescribed quality and identity standards at every stage of the supply chain, covering procurement, purchasing, storage, distribution and transportation, along with mandatory documentation and record-keeping.
 
The framework builds on GSDP guidance developed by the Central Drugs Standard Control Organisation (CDSCO) and aims to ensure that the quality established during manufacturing is not compromised during subsequent storage or transportation.
 
The proposed amendment is also expected to strengthen regulatory oversight, inspection and enforcement by Central and State drug-control authorities.
 
It will place greater emphasis on documentation, traceability and accountability across the pharmaceutical distribution network, including manufacturers, importers, wholesalers, distributors, stockists and other entities involved in supplying medicines.
 
Maintaining appropriate storage and transportation conditions is critical to preventing pharmaceutical products from losing their quality or integrity after leaving manufacturing facilities. The proposed framework seeks to ensure that medicines remain within specified quality and environmental conditions throughout their journey.
 
By strengthening safeguards against contamination, falsification, diversion and unauthorised distribution, the government aims to improve the reliability of the pharmaceutical supply chain and reinforce quality assurance for patients and healthcare providers.
 
The proposed amendment marks another step towards strengthening India's pharmaceutical quality-management system, with the stated objective of ensuring that medicines reaching patients meet the quality standards maintained at the manufacturing stage.

Upcoming E-conference

Other Related stories

Startup

Digitization

Collaborative models are practical way to build capability in biologics: Manoj Kumar Panicker, Cytiva and Dr. Sanjib Banerjee, Veeda Lifesciences
Collaborative models are practical way to build capability in biologics: Manoj Kumar Panicker, Cytiva and Dr. Sanjib Banerjee, Veeda Lifesciences
(L-R) Manoj Kumar Panicker, General Manager, South Asia, Cytiva and Dr. Sanjib Banerjee, Chief Operating Officer (Biopharma Services), Veeda Lifesciences.